Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice
Florence Njau, Nelli Shushakova, Heiko Schenk, Vera Christine Wulfmeyer, Robin Bollin, Jan Menne, Hermann Haller, Florence Njau, Nelli Shushakova, Heiko Schenk, Vera Christine Wulfmeyer, Robin Bollin, Jan Menne, Hermann Haller
Abstract
Inhibiting vascular endothelial growth factor (VEGF) is a therapeutic option in diabetic microangiopathy. However, VEGF is needed at physiological concentrations to maintain glomerular integrity; complete VEGF blockade has deleterious effects on glomerular structure and function. Anti-VEGF therapy in diabetes raises the challenge of reducing VEGF-induced pathology without accelerating endothelial cell injury. Heparan sulfate (HS) act as a co-receptor for VEGF. Calcium dobesilate (CaD) is a small molecule with vasoprotective properties that has been used for the treatment of diabetic microangiopathy. Preliminary evidence suggests that CaD interferes with HS binding sites of fibroblast growth factor. We therefore tested the hypotheses that (1) CaD inhibits VEGF signaling in endothelial cells, (2) that this effect is mediated via interference between CaD and HS, and (3) that CaD ameliorates diabetic nephropathy in a streptozotocin-induced diabetic mouse model by VEGF inhibition. We found that CaD significantly inhibited VEGF165-induced endothelial cell migration, proliferation, and permeability. CaD significantly inhibited VEGF165-induced phosphorylation of VEGFR-2 and suppressed the activity of VEGFR-2 mediated signaling cascades. The effects of CaD in vitro were abrogated by heparin, suggesting the involvement of heparin-like domain in the interaction with CaD. In addition, VEGF121, an isoform which does not bind to heparin, was not inhibited by CaD. Using the proximity ligation approach, we detected inhibition of interaction in situ between HS and VEGF and between VEGF and VEGFR-2. Moreover, CaD reduced VEGF signaling in mice diabetic kidneys and ameliorated diabetic nephropathy and neuropathy, suggesting CaD as a VEGF inhibitor without the negative effects of complete VEGF blockade and therefore could be useful as a strategy in treating diabetic nephropathy.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002;51: 3090–3094. 10.2337/diabetes.51.10.3090
- Group TDC and CT of DI and CR. Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. N Engl J Med. 2000;342: 381–389. 10.1056/NEJM200002103420603
- Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed). 1987;294: 1443–7. 10.1136/bmj.294.6585.1443
- Bakris GL, Ritz E. The message for World Kidney Day 2009: Hypertension and kidney disease—A marriage that should be prevented. Journal of Hypertension. 2009. pp. 666–669. 10.1097/HJH.0b013e328327706a
- Wu HY, Huang JW, Lin HJ, Liao W-CC, Peng Y-SS, Hung KY, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347: f6008 10.1136/bmj.f6008
- Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. US renal data system 2011 Annual data report. Am J Kidney Dis. 2012;59: 6386 10.1053/j.ajkd.2011.11.015
- Nelson RG, Newman JM, Knowler WC, Sievers ML, Kunzelman CL, Pettitt DJ, et al. Incidence of end-stage renal disease in Type 2 (non-insulin-dependent) diabetes mellitus in pima indians. Diabetologia. 1988;31: 730–736. 10.1007/bf00274774
- Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocrine Reviews. 2001. pp. 36–52. 10.1210/edrv.22.1.0417
- Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48: 2229–2239. 10.2337/diabetes.48.11.2229
- Braun L, Kardon T, Reisz-Porszasz ZS, Banhegyi G, Mandl J. The regulation of the induction of vascular endothelial growth factor at the onset of diabetes in spontaneously diabetic rats. Life Sci. 2001;69: 2533–42. 10.1016/s0024-3205(01)01327-3
- Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CPM. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2006;69: 1654–1661.
- Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney International. 2004. pp. 2003–2017.
- Wang W, Merrill MJ, Borchardt RT. Vascular endothelial growth factor affects permeability of brain microvessel endothelial cells in vitro. Am J Physiol. 1996;271: C1973–80. 10.1152/ajpcell.1996.271.6.C1973
- De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. JAmSocNephrol. 2001;12: 993–1000.
- Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;265: H586–92. 10.1152/ajpheart.1993.265.2.H586
- Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes. 2009;58: 1471–1478. 10.2337/db09-0119
- Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87: 3336–3343.
- Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH, De Vriese AS. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant. 2006;21: 324–329. 10.1093/ndt/gfi217
- Lai X-X, Xu R-A, Yu-Ping L, Yang H. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther. 2016;9: 2421–8. 10.2147/OTT.S96156
- Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. Journal of the American Society of Nephrology. 2019. 10.1681/ASN.2018080853
- Eremina V, Quaggin SE. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol. 2010;30: 582–590. 10.1016/j.semnephrol.2010.09.006
- Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF Inhibition and Renal Thrombotic Microangiopathy. N Engl J Med. 2008;358: 1129–1136. 10.1056/NEJMoa0707330
- Zhang XY, Liu W, Wu SS, Jin JL, Li WH, Wang NL. Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis. Sci China Life Sci. 2014;58: 101–107. 10.1007/s11427-014-4792-1
- Javadzadeh A, Ghorbanihaghjo A, Adl FH, Andalib D, Khojasteh-Jafari H, Ghabili K. Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis. 2013;19: 62–68.
- Zhou Y, Yuan J, Qi C, Shao X, Mou S, Ni Z. Calcium dobesilate may alleviate diabetes-induced endothelial dysfunction and inflammation. Mol Med Rep. 2017;16: 8635–8642. 10.3892/mmr.2017.7740
- Zhang X. Therapeutic effects of calcium dobesilate on diabetic nephropathy mediated through reduction of expression of PAI-1. Exp Ther Med. 2013;5: 295–299. 10.3892/etm.2012.755
- Fernández IS, Cuevas P, Angulo J, López-Navajas P, Canales-Mayordomo Á, González-Corrochano R, et al. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem. 2010;285: 11714–11729. 10.1074/jbc.M109.064618
- Angulo J, Cuevas P, Cuevas B, El Youssef M, Fernández A, Martínez-Salamanca E, et al. Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities. J Transl Med. 2015. 10.1186/s12967-015-0413-4
- Thamm K, Njau F, Van Slyke P, Dumont DJ, Park J-K, Haller H, et al. Pharmacological Tie2 activation in kidney transplantation. World J Transplant. 2016;6: 573 10.5500/wjt.v6.i3.573
- Martins-Green M, Petreaca M, Yao M. Chapter 8 An Assay System for In Vitro Detection of Permeability in Human “Endothelium.” Methods in Enzymology. 2008. pp. 137–153. 10.1016/S0076-6879(08)02008-9
- Goncalves V, Gautier B, Garbay C, Vidal M, Inguimbert N. Development of a chemiluminescent screening assay for detection of vascular endothelial growth factor receptor 1 ligands. Anal Biochem. 2007;366: 108–110. 10.1016/j.ab.2007.03.027
- Angulo J, Peiró C, Romacho T, Fernández A, Cuevas B, González-Corrochano R, et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol. 2011;667: 153–159. 10.1016/j.ejphar.2011.06.015
- Tornavaca O, Chia M, Dufton N, Almagro LO, Conway DE, Randi AM, et al. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. J Cell Biol. 2015. 10.1083/jcb.201404140
- González-Mariscal L, Betanzos A, Ávila-Flores A. MAGUK proteins: Structure and role in the tight junction. Semin Cell Dev Biol. 2000. 10.1006/scdb.2000.0178
- Edward Conrad H, Edward Conrad H. Chapter 2 –Structures of Heparinoids. Heparin-Binding Proteins. 1998. pp. 7–60. 10.1016/B978-012186060-8/50003-6
- Ashikari-Hada S, Habuchi H, Kariya Y, Kimata K. Heparin Regulates Vascular Endothelial Growth Factor 165 -dependent Mitogenic Activity, Tube Formation, and Its Receptor Phosphorylation of Human Endothelial Cells. J Biol Chem. 2005;280: 31508–31515. 10.1074/jbc.M414581200
- Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem. 1992;267: 6093–6098.
- Wijelath E, Namekata M, Murray J, Furuyashiki M, Zhang S, Coan D, et al. Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J Cell Biochem. 2010;111: 461–468. 10.1002/jcb.22727
- Park M, Lee ST. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem Biophys Res Commun. 1999;264: 730–734. 10.1006/bbrc.1999.1580
- Dougher AM, Wasserstrom H, Torley L, Shridaran L, Westdock P, Hileman RE, et al. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors. 1997;14: 257–268. 10.3109/08977199709021524
- Nishiguchi KM, Kataoka K, Kachi S, Komeima K, Terasaki H. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS One. 2010;5 10.1371/journal.pone.0013493
- Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, et al. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem. 1994.
- Cuevas P, Arrazola JM. Dobesilate in the treatment of plaque psoriasis. Eur J Med Res. 2005;10: 373–376.
- Cuevas P, Arrazola JM. Therapeutic response of rosacea to dobesilate. Eur J Med Res. 2005;10: 454–456.
- Yang W, Yu X, Zhang Q, Lu Q, Wang J, Cui W, et al. Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor. Exp Eye Res. 2013;115: 96–105. 10.1016/j.exer.2013.06.011
- Haller H, Ji L, Stahl K, Bertram A, Menne J. Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilate—Free Radical Scavenger and Growth Factor Inhibition. Biomed Res Int. 2017;2017: 1–11. 10.1155/2017/1909258
- Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling. 2007. pp. 2003–2012. 10.1016/j.cellsig.2007.05.013
- Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes and Cancer. 2011;2: 1097–1105. 10.1177/1947601911423031
- Cerezo AB, Hornedo-Ortega R, Álvarez-Fernández MA, Troncoso AM, García-Parrilla MC. Inhibition of VEGF-induced VEGFR-2 activation and HUVEC migration by melatonin and other bioactive indolic compounds. Nutrients. 2017;9 10.3390/nu9030249
- Fish JE, Gutierrez MC, Dang LT, Khyzha N, Chen Z, Veitch S, et al. Dynamic regulation of VEGF-inducible genes by an ERK/ERG/p300 transcriptional network. Dev. 2017. 10.1242/dev.146050
- Cuevas P, Díaz-Gonzalez D, García-Martín-Córdova C, Sánchez I, Lozano RM, Giménez-Gallego G, et al. Dobesilate diminishes activation of the mitogen—activated protein kinase ERK1/2 in glioma cells. J Cell Mol Med. 2006;10: 225–230. 10.1111/j.1582-4934.2006.tb00303.x
- Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J, et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes. 2010;59: 2637–2645. 10.2337/db09-1421
- Solà-Adell C, Bogdanov P, Hernández C, Sampedro J, Valeri M, Garcia-Ramirez M, et al. Calcium Dobesilate Prevents Neurodegeneration and Vascular Leakage in Experimental Diabetes. Curr Eye Res. 2017;42: 1273–1286. 10.1080/02713683.2017.1302591
- Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, et al. Increased Expression of Vascular Endothelial Growth Factor in Kidney Leads to Progressive Impairment of Glomerular Functions. J Am Soc Nephrol. 2007;18: 2094–2104. 10.1681/ASN.2006010075
- Teran M, Nugent MA. Synergistic binding of vascular endothelial growth factor-a and its receptors to heparin selectively modulates complex affinity. J Biol Chem. 2015. 10.1074/jbc.M114.627372
- Leung D, Cachianes G, Kuang W, Goeddel D, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (80-). 1989;246: 1306–1309. 10.1126/science.2479986
- Kiyan Y, Tkachuk S, Kurselis K, Shushakova N, Stahl K, Dawodu D, et al. Heparanase-2 protects from LPS-mediated endothelial injury by inhibiting TLR4 signalling. Sci Rep. 2019. 10.1038/s41598-019-50068-5
- Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited. Cancer Cell. 2009. pp. 167–170. 10.1016/j.ccr.2009.02.007
- Bogdanov P, Solà-Adell C, Hernández C, García-Ramírez M, Sampedro J, Simó-Servat O, et al. Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice. J Diabetes Complications. 2017;31: 1481–1490. 10.1016/j.jdiacomp.2017.07.009
- Zhou Y, Qi C, Li S, Shao X, Mou S, Ni Z. Diabetic nephropathy can be treated with calcium dobesilate by alleviating the chronic inflammatory state and improving endothelial cell function. Cell Physiol Biochem. 2018. 10.1159/000495491
- Solà-Adell C, Bogdanov P, Hernández C, Sampedro J, Valeri M, Garcia-Ramirez M, et al. Calcium Dobesilate Prevents Neurodegeneration and Vascular Leakage in Experimental Diabetes. Curr Eye Res. 2017;42: 1273–1286. 10.1080/02713683.2017.1302591
- Han K, Liu C, Shi X, Rao X. Effects of alprostadil combined with calcium dobesilate in patients with diabetic peripheral neuropathy. Neuroendocrinol Lett. 2018.
- Tejerina T, Ruiz E. Calcium dobesilate: Pharmacology and future approaches. General Pharmacology. 1998. pp. 357–360. 10.1016/S0306-3623(98)00040-8
- Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treatments in Endocrinology. 2005. pp. 221–232. 10.2165/00024677-200504040-00003
- Tanabe K, Maeshima Y, Sato Y, Wada J. Antiangiogenic Therapy for Diabetic Nephropathy. Biomed Res Int. 2017;2017: 1–12. 10.1155/2017/5724069
Source: PubMed